Skip to main content
search
 

21 CFR 54 - FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS

Title 21 published on 2011-04-01

no entries appear in the Federal Register after this date.

This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.

This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].

It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.


United States Code

21 USC 321 - Definitions; generally

21 USC 331 - Prohibited acts

21 USC 351 - Adulterated drugs and devices

21 USC 352 - Misbranded drugs and devices

21 USC 353 - Exemptions and consideration for certain drugs, devices, and biological products

21 USC 355 - New drugs

21 USC 360 - Registration of producers of drugs or devices

21 USC 360c - Classification of devices intended for human use

21 USC 360d - Performance standards

21 USC 360e - Premarket approval

21 USC § 360e–1 - Pediatric uses of devices

21 USC 360f - Banned devices

21 USC 360g - Judicial review

21 USC 360h - Notification and other remedies

21 USC 360i - Records and reports on devices

21 USC 360j - General provisions respecting control of devices intended for human use

21 USC 371 - Regulations and hearings

21 USC 372 - Examinations and investigations

21 USC 373 - Records

21 USC 374 - Inspection

21 USC 375 - Publicity

21 USC 376 - Examination of sea food on request of packer; marking food with results; fees; penalties

21 USC 379 - Confidential information